litlas
Log inCreate account

Rolf Kiessling

Active 1975–2024

126
Papers
24,145
Citations
90
h-index
126
i10-index

Citations

Citations per year for Rolf Kiessling1975: 14 citations1976: 33 citations1977: 56 citations1978: 56 citations1979: 85 citations1980: 72 citations1981: 69 citations1982: 49 citations1983: 31 citations1984: 28 citations1985: 37 citations1986: 20 citations1987: 39 citations1988: 8 citations1989: 57 citations1990: 38 citations1991: 38 citations1992: 27 citations1993: 40 citations1994: 37 citations1995: 35 citations1996: 70 citations1997: 75 citations1998: 72 citations1999: 110 citations2000: 94 citations2001: 140 citations2002: 179 citations2003: 148 citations2004: 172 citations2005: 182 citations2006: 154 citations2007: 138 citations2008: 161 citations2009: 131 citations2010: 118 citations2011: 177 citations2012: 187 citations2013: 187 citations2014: 199 citations2015: 244 citations2016: 198 citations2017: 194 citations2018: 210 citations2019: 536 citations2020: 618 citations2021: 592 citations2022: 472 citations2023: 358 citations2024: 484 citations2025: 247 citations2026: 8 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,488 citing papers, 28.3% of this breakdownChina: 974 citing papers, 11.1% of this breakdownGermany: 578 citing papers, 6.6% of this breakdownUnited Kingdom: 443 citing papers, 5.1% of this breakdownSweden: 427 citing papers, 4.9% of this breakdownItaly: 419 citing papers, 4.8% of this breakdownFrance: 355 citing papers, 4% of this breakdownJapan: 276 citing papers, 3.1% of this breakdownNetherlands: 261 citing papers, 3% of this breakdownCanada: 230 citing papers, 2.6% of this breakdownAustralia: 197 citing papers, 2.2% of this breakdownSpain: 174 citing papers, 2% of this breakdown
0%28.3%Other 22.3%

Institutions

Fields

  • Immunology and Microbiology50%
  • Medicine31.5%
  • Biochemistry, Genetics and Molecular Biology14.5%
  • Engineering1%
  • Neuroscience0.9%
  • Nursing0.5%
  • Other1.6%

Topics

  • Immune Cell Function and Interaction13.4%
  • Immunotherapy and Immune Responses7.7%
  • T-cell and B-cell Immunology6.6%
  • CAR-T cell therapy research6.3%
  • Cancer Immunotherapy and Biomarkers6.1%
  • Immune cells in cancer5.2%
  • Other54.7%

Coauthors

All papers

Open in search
  1. Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy

    Authors: Klas Kärre, Hans Ljunggren, Gerald E. Piontek, Rolf Kiessling - Nature 1986 cited by 2,152

  2. Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells

    Authors: Silke Eisinger, Dhifaf Sarhan, Vanessa F. Boura, Itziar Ibarlucea-Benitez, Sofia Tyystjärvi, Ganna Oliynyk, Marie Arsenian‐Henriksson, David P. Lane, Stina L. Wikström, Rolf Kiessling, Tommaso Virgilio, Santiago González, Dagmara Kaczyńska, Shigeaki Kanatani, Evangelia Daskalaki, Craig E. Wheelock, Saikiran K. Sedimbi, Benedict J. Chambers, Jeffrey V. Ravetch, Mikael C. I. Karlsson - National Academy of Sciences, Proceedings of the National Academy of Sciences 2020 cited by 176

  3. Counteracting CAR T cell dysfunction

    Authors: Mansour Poorebrahim, Jeroen Melief, Yago Pico de Coaña, Stina L. Wickström, Ángel Cid-Arregui, Rolf Kiessling - Oncogene 2020 cited by 166

  4. „Natural” killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype

    Authors: Rolf Kiessling, Eva Klein, Hans Wigzell - European Journal of Immunology 1975 cited by 1,784

  5. Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress

    Authors: Stefanie Renken, Takahiro Nakajima, Isabelle Magalhaes, Jonas Mattsson, Andreas Lundqvist, Elias S.J. Arnér, Rolf Kiessling, Stina L. Wickström - Journal for ImmunoTherapy of Cancer 2022 cited by 62

  6. Coexpressed Catalase Protects Chimeric Antigen Receptor–Redirected T Cells as well as Bystander Cells from Oxidative Stress–Induced Loss of Antitumor Activity

    Authors: Maarten A. Ligtenberg, Dimitrios Mougiakakos, Madhura Mukhopadhyay, Kristina Witt, Álvaro Lladser, Markus Chmielewski, Tobias Riët, Hinrich Abken, Rolf Kiessling - The Journal of Immunology 2015 cited by 212

  7. „Natural” killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell

    Authors: Rolf Kiessling, Eva Klein, Hugh F. Pross, Hans Wigzell - European Journal of Immunology 1975 cited by 1,116

  8. Classification of current anticancer immunotherapies

    Authors: Lorenzo Galluzzi, Erika Vacchelli, José Manuel Bravo‐San Pedro, Aitziber Buqué, Laura Senovilla, Elisa Elena Baracco, Norma Bloy, Francesca Castoldi, Jean-Pierre Abastado, Patrizia Agostinis, Ron N. Apte, Fernando Aranda, Maha Ayyoub, Philipp Beckhove, Jean‐Yves Blay, Laura Bracci, Anne Caignard, Chiara Castelli, Federica Cavallo, Estaban Celis, Vincenzo Cerundolo, Aled Clayton, Mario P. Colombo, Lisa M. Coussens, Madhav V. Dhodapkar, Alexander Eggermont, Douglas T. Fearon, Wolf H. Fridman, Jitka Fučíková, Dmitry I. Gabrilovich, Jérôme Galon, Abhishek D. Garg, François Ghiringhelli, Giuseppe Giaccone, Eli Gilboa, Sacha Gnjatic, Axel Hoos, Anne Hosmalin, Dirk Jäger, Paweł Kaliński, Klas Kärre, Oliver Kepp, Rolf Kiessling, John M. Kirkwood, Eva Klein, Alexander Knuth, Claire E. Lewis, Roland Liblau, Michael T. Lotze, Enrico Lugli, J P Mach, Fabrizio Mattei, Domenico Mavilio, Ignacio Melero, Cornelis J.M. Melief, Elizabeth A. Mittendorf, Lorenzo Moretta, Adekunke Odunsi, Hideho Okada, A. Karolina Palucka, Marcus E. Peter, Kenneth J. Pienta, Angel Porgador, George C. Prendergast, Gabriel A. Rabinovich, Nicholas P. Restifo, Naiyer A. Rizvi, Catherine Sautès‐Fridman, Hans Schreiber, Barbara Seliger, Hiroshi Shiku, Bruno Silva‐Santos, Mark J. Smyth, Daniel E. Speiser, Radek Špíšek, Pramod K. Srivastava, James E. Talmadge, Éric Tartour, Sjoerd H. van der Burg, Benoı̂t J. Van den Eynde, Richard G. Vile, Hermann Wagner, Jeffrey S. Weber, Theresa L. Whiteside, Jedd D. Wolchok, Laurence Zitvogel, Weiping Zou, Guido Kroemer - Oncotarget 2014 cited by 470

  9. Tumor-associated NK cells drive MDSC-mediated tumor immune tolerance through the IL-6/STAT3 axis

    Authors: Shiyong Neo, Le Tong, Joni Chong, Yaxuan Liu, Jing Xu, Mariana M.S. Oliveira, Yi Chen, Ziqing Chen, Keene Lee, Nutsa Burduli, Xinsong Chen, Juan Gao, Ran Ma, Jia Pei Lim, Jianxin Huo, Shengli Xu, Evren Alici, Stina L. Wickström, Felix Haglund, Johan Hartman, Arnika Kathleen Wagner, Yihai Cao, Rolf Kiessling, Kong‐Peng Lam, Lisa S. Westerberg, Andreas Lundqvist - Science Translational Medicine 2024 cited by 70

  10. Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality

    Authors: Esther Schoutrop, Stefanie Renken, Isabella Micallef Nilsson, Paula Hahn, Thomas Poiret, Rolf Kiessling, Stina L. Wickström, Jonas Mattsson, Isabelle Magalhaes - OncoImmunology 2022 cited by 38

  11. Increased thioredoxin-1 production in human naturally occurring regulatory T cells confers enhanced tolerance to oxidative stress

    Authors: Dimitrios Mougiakakos, C. Christian Johansson, Regina Jitschin, Martin Böttcher, Rolf Kiessling - Blood 2010 cited by 163

  12. Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma

    Authors: Yago Pico de Coaña, Maria Wolodarski, Isabel Poschke, Yuya Yoshimoto, Yuan Yang, Maria Nyström, Ulrika Edbäck, Suzanne Eghyazi Brage, Andreas Lundqvist, Giuseppe Masucci, Johan Hansson, Rolf Kiessling - Oncotarget 2017 cited by 142

  13. The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones

    Authors: Isabel Poschke, Jessica C. Hassel, Aaron Rodriguez-Ehrenfried, Katharina A.M. Lindner, Ignacio Heras‐Murillo, Lena M. Appel, Johanna Lehmann, Tanja Lövgren, Stina L. Wickström, Claudia Lauenstein, Jasmin Roth, Anna‐Katharina König, John B.A.G. Haanen, Joost van den Berg, Rolf Kiessling, Frank Bergmann, Michael Floßdorf, Oliver Strobel, Rienk Offringa - Clinical Cancer Research 2020 cited by 90

  14. Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity

    Authors: Yumeng Mao, Dhifaf Sarhan, André Steven, Barbara Seliger, Rolf Kiessling, Andreas Lundqvist - Clinical Cancer Research 2014 cited by 269

  15. Primary Human Tumor Cells Expressing CD155 Impair Tumor Targeting by Down-Regulating DNAM-1 on NK Cells

    Authors: Mattias Carlsten, Håkan Norell, Yenan T. Bryceson, Isabel Poschke, Kjell Schedvins, Hans‐Gustaf Ljunggren, Rolf Kiessling, Karl‐Johan Malmberg - The Journal of Immunology 2009 cited by 276

  16. The human antimicrobial and chemotactic peptides LL-37 and α-defensins are expressed by specific lymphocyte and monocyte populations

    Authors: Birgitta Agerberth, Jehad Charo, Joachim Werr, Berit Olsson, Farah Idali, Lennart Lindbom, Rolf Kiessling, Hans Jörnvall, Hans Wigzell, Guðmundur H. Guðmundsson - Blood 2000 cited by 748

  17. Regulatory T Cells in Cancer

    Authors: Dimitrios Mougiakakos, Aniruddha Choudhury, Álvaro Lladser, Rolf Kiessling, C. Christian Johansson - Advances in cancer research 2010 cited by 382

  18. Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas

    Authors: Anna Kruschinski, Andreas Moosmann, Isabel Poschke, Håkan Norell, Markus Chmielewski, Barbara Seliger, Rolf Kiessling, Thomas Blankenstein, Hinrich Abken, Jehad Charo - National Academy of Sciences, Proceedings of the National Academy of Sciences 2008 cited by 195

  19. Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stress–induced cell death

    Authors: Dimitrios Mougiakakos, C. Christian Johansson, Rolf Kiessling - Blood 2008 cited by 187

  20. Melanoma-Educated CD14+ Cells Acquire a Myeloid-Derived Suppressor Cell Phenotype through COX-2–Dependent Mechanisms

    Authors: Yumeng Mao, Isabel Poschke, Erik Wennerberg, Yago Pico de Coaña, Suzanne Egyházi Brage, Inkeri Schultz, Johan Hansson, Giuseppe Masucci, Andreas Lundqvist, Rolf Kiessling - Cancer Research 2013 cited by 186

  21. Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination

    Authors: Tanja Lövgren, Maria Wolodarski, Stina L. Wickström, Ulrika Edbäck, Mette Wallin, Eva Martell, Katrin Markland, Pontus Blomberg, Maria Nyström, Andreas Lundqvist, Hans Jacobsson, Gustav Ullenhag, Per Ljungman, Johan Hansson, Giuseppe Masucci, Roger Tell, Isabel Poschke, Lars Adamson, Jonas Mattsson, Rolf Kiessling - OncoImmunology 2020 cited by 50

  22. Hydrogen peroxide secreted by tumor‐derived macrophages down‐modulates signal‐transducing zeta molecules and inhibits tumor‐specific T cell‐and natural killer cell‐mediated cytotoxicity

    Authors: Koji Kono, Flavio Salazar‐Onfray, Max Petersson, Johan Hansson, Giuseppe Masucci, Ken Wasserman, Tsutomu Nakazawa, Paul Anderson, Rolf Kiessling - European Journal of Immunology 1996 cited by 361

  23. Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma

    Authors: Yumeng Mao, Nina Eißler, Katarina Le Blanc, John Inge Johnsen, Per Kogner, Rolf Kiessling - Clinical Cancer Research 2016 cited by 141

  24. Ipilimumab Treatment Results in an Early Decrease in the Frequency of Circulating Granulocytic Myeloid-Derived Suppressor Cells as well as Their Arginase1 Production

    Authors: Yago Pico de Coaña, Isabel Poschke, Giusy Gentilcore, Yumeng Mao, Maria Nyström, Johan Hansson, Giuseppe Masucci, Rolf Kiessling - Cancer Immunology Research 2013 cited by 138